Cencora

(New York Stock Exchange)
Back to all articles
Slightly Bullish +25

First Horizon Corp Lowers Position in Cencora, Inc. $COR

AI-generated analysis

πŸ“‰ First Horizon Corp trimmed its Cencora position by 36.5% in Q1, reducing holdings to 6,506 shares worth $2.04 million.

πŸ“ˆ United Bank increased its stake by 4.5% in Q2, while DZ BANK AG boosted its position by 26.0% to own $22.025 million in stock.

πŸ’° Cencora announced a new $2.00 billion stock repurchase plan authorized by the Board of Directors on May 21st.

πŸ“Š The company reported Q1 revenue of $78.36 billion, up 3.9% year-over-year, though it missed EPS estimates by $0.07.

🎯 Analyst consensus remains a 'Moderate Buy' with an average price target of $367.75, despite mixed individual bank targets ranging from $285 to $420.

πŸ’΅ Cencora paid a quarterly dividend of $0.60 on June 1st, representing a 0.8% yield and an 18.40% payout ratio.

πŸ‘” Director Lauren M. Tyler purchased 550 shares at $270.23 per share, increasing her personal ownership by 14.44%.

πŸ“‰ The stock currently trades at a P/E ratio of 23.26 with a market cap of $59.01 billion and a beta of 0.58.

πŸ₯ Cencora provides critical pharmaceutical distribution, specialty pharmacy services, and cold-chain logistics for temperature-sensitive therapies.

Bullish Signals
  • Cencora initiated a $2.00 billion stock repurchase program, signaling management's belief that shares are undervalued.
  • Revenue grew by 3.9% year-over-year to $78.36 billion, demonstrating continued top-line expansion despite missing earnings estimates.
  • The company maintains an exceptionally high return on equity of 135.20%, indicating strong capital efficiency.
  • Major institutional investors like DZ BANK AG and United Bank increased their stakes significantly in the second quarter.
  • Analysts maintain a 'Moderate Buy' consensus with an average price target of $367.75, which is above the current trading price.
Risk Factors
  • Cencora missed Q1 earnings expectations by $0.07 per share, reporting $4.75 EPS against a consensus of $4.82.
  • Revenue of $78.36 billion fell short of analyst expectations of $81.09 billion for the quarter.
  • The stock trades below its 200-day moving average of $318.98, indicating some near-term weakness relative to longer-term trends.
  • Current liquidity ratios are tight, with a current ratio of 0.95 and a quick ratio of 0.59.
Full Analysis
First Horizon Corp reduced its stake in Cencora, Inc. (NYSE:COR) by 36.5% during the first quarter, selling 3,747 shares to hold a remaining position of 6,506 shares valued at $2,044,000. This move contrasts with several other institutional investors who increased their holdings in the second quarter, including United Bank, Nebula Research & Development LLC, and DZ BANK AG, which collectively added significant capital to their positions. Analyst sentiment remains mixed but generally positive regarding Cencora's long-term prospects. Major banks like Morgan Stanley and Evercore maintain high price targets of $342 and $360 respectively, while Bank of America raised its target to $285 with a neutral rating. Conversely, Robert W. Baird lowered its target to $339, and Barclays cut its target to $350, though both maintained buy or overweight ratings. Financially, Cencora reported Q1 earnings of $4.75 EPS, missing the consensus estimate of $4.82, with revenue of $78.36 billion falling short of the $81.09 billion expectation. Despite the miss, the company grew revenue by 3.9% year-over-year and maintains a robust return on equity of 135.20%. The firm has initiated a $2.00 billion stock repurchase program and pays a quarterly dividend of $0.60. The company operates as a global leader in healthcare services and pharmaceutical distribution, providing end-to-end solutions including wholesale drug distribution, specialty pharmacy operations, and cold-chain management for temperature-sensitive therapies. With a market capitalization of $59.01 billion and an average analyst target price of $367.75, the stock trades above its 50-day moving average but below its 200-day moving average.